MY ACCOUNT | NEWSLETTER |

Felycin wins FDA conditional pathway nod


Animal health R&D company, TriviumVet, has the received FDA Center for Veterinary Medicine’s approval to move forward within the expanded conditional process for Felycin™, a therapy for feline hypertrophic cardiomyopathy. The pathway allows Trivium to market the drug while pivotal clinical trials are ongoing as the drug has been deemed safe and meets compliant manufacturing standards. 

The pathway is also a mechanism to enhance treatment options for diseases which currently have no approved therapies. In the US, there is no approved drug for feline hypertrophic cardiomyopathy, or feline HCM, a disease which is estimated to impact about 15% of cat companions in the country.

"We are very pleased with this positive response from CVM as it establishes a pathway to first conditional and then full approval, potentially expediting access to the drug for millions of at-risk patients,” said Louise Grubb, chief executive officer at TriviumVet. “We are excited to share results of our clinical work early next year and intend to submit our final study report to CVM once these results are available.”

The pivotal trial will study delayed-release Felycin (rapamycin) in cats after laboratory research and use in human patients who received organ transplants indicated improvement in cardiac parameters in patients with HCM. 


Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

World Veterinary Dermatology Day

Like0
Dislike0

Artificial insemination market to grow to $3B by 2028

Like0
Dislike0

February is National Pet Dental Health Month

Like0
Dislike0

Falling markets? Don't panic, it's not the first time

Like0
Dislike0

Treatment of canine chronic cutaneous lupus erythematosus with oclacitinib

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2023 - All Rights Reserved
ISSN 2768-198X

Top